Phase 1-2 Study of ASTX660 in Subjects With Advanced Solid Tumors and Lymphomas (NCT02503423)

🧪 Interventions in This Study

• ASTX660 (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (68 Sites)

Showing the first 25 of 68 sites.

• University of Alabama at Birmingham — Birmingham, Alabama
• HonorHealth Research Institute — Scottsdale, Arizona
• USC/Norris Comprehensive Cancer Center — Los Angeles, California
• Cedars-Sinai Medical Center — Los Angeles, California
• UC Davis Medical Center — Sacramento, California
• Simlow Cancer Hospital at Yale — New Haven, Connecticut
• Emory University winship Cancer Institute — Atlanta, Georgia
• Robert H. Lurie Comprehensive Cancer Center of Northwestern University — Chicago, Illinois
• The Sidney Kimmel Comprehensive Cancer Center at John Hopkins — Baltimore, Maryland
• Tufts Medical Center — Boston, Massachusetts
• Dana-Farber Cancer Institute — Boston, Massachusetts
• University of Michigan — Ann Arbor, Michigan
• Dartmouth-Hitchcock Medical Center (DHMC) — Lebanon, New Hampshire
• Summit Medical Group - Florham Park Campus/Atlantic Health — Florham Park, New Jersey
• Roswell Park Cancer Institute — Buffalo, New York
• New York University Langone Medical Center — New York, New York
• New York Presbyterian Hospital Columbia University Medical Center — New York, New York
• Icahn School of Medicine at Mount Sinai — New York, New York
• Rochester Skin Lymphoma Medical Group — Rochester, New York
• Wake Forest Baptist Health — Winston-Salem, North Carolina
• The Ohio State University and Wexner Medical Center, James Cancer Hospital — Columbus, Ohio
• University of Oklahoma Stephenson Cancer Center — Oklahoma City, Oklahoma
• Oregon Health and Science University — Portland, Oregon
• West Penn Hospital — Pittsburgh, Pennsylvania
• Hollings Cancer Center — Charleston, South Carolina

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Solid Tumors

• Study of Pembrolizumab Following Surgery in Patients With Microsatellite Instability High (MSI-H) Solid Tumors — Basking Ridge, New Jersey
• Study of the Effect of Rifampicin on the Pharmacokinetics (PK) of Multiple Doses of Cediranib in Patients With Solid Tumours — Edmonton, Alberta
• Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor) — Santa Monica, California
• A Safety and Efficacy Extension Study of Pertuzumab in Patients With Solid Tumors Previously Enrolled in a Hoffmann-La Roche-Sponsored Pertuzumab Clinical Trial — Porto Alegre, Rio Grande do Sul
• Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants With Solid Tumors — Los Angeles, California
• Flavored, Oral Irinotecan VAL-413 (Orotecan®) Given With Temozolomide for Treatment of Recurrent Pediatric Solid Tumors — Phoenix, Arizona

Explore by condition: All Solid Tumors clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Review the official NIH record below to find the coordinating site.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.